December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Intravitreal Toxicology and Pharmacokinetics of 1-O-hexadecylpropanediol-3-phospho arabinosides
Author Affiliations & Notes
  • L-Y Cheng
    Department of Ophthalmology Shiley Eye Center UCSD La Jolla CA
  • KY Hostetler
    Department of Medicine VA Medical Center and UCSD La Jolla CA
  • JR Beadle
    Department of Medicine VA Medical Center and UCSD La Jolla CA
  • M Toyoguchi
    Department of Ophthalmology Shiley Eye Center UCSD La Jolla CA
  • K Aldern
    Department of Medicine VA Medical Center and UCSD La Jolla CA
  • N Rodanant
    Department of Ophthalmology Shiley Eye Center UCSD La Jolla CA
  • G Bergeron-Lynn
    Department of Ophthalmology Shiley Eye Center UCSD La Jolla CA
  • WR Freeman
    Department of Ophthalmology Shiley Eye Center UCSD La Jolla CA
  • Footnotes
    Commercial Relationships   L. Cheng, None; K.Y. Hostetler, None; J.R. Beadle, None; M. Toyoguchi, None; K. Aldern, None; N. Rodanant, None; G. Bergeron-Lynn, None; W.R. Freeman, None. Grant Identification: NIH EY 07366 and NIH EY 11832
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2802. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L-Y Cheng, KY Hostetler, JR Beadle, M Toyoguchi, K Aldern, N Rodanant, G Bergeron-Lynn, WR Freeman; Intravitreal Toxicology and Pharmacokinetics of 1-O-hexadecylpropanediol-3-phospho arabinosides . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2802.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:We have demonstrated a prototype of long-lasting intraocular drug delivery system using crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir (HDP-P-GCV) (IOVS February 2002). In order to further characterize this novel system, crystalline 1-O-hexadecylpropanediol-3-phospho cytosine arabinoside, HDP-P-Ara-C was synthesized and its intraocular profile of pharmacology was studied after intravitreal injection. Methods:HDP-Ara-C was synthesized by coupling HDP-phosphate to the 5' hydroxyl of Ara-C. The crystalline HDP-P-Ara-C was added into 5% dextrose and the solution was intravitreally injected with resultant concentrations of 0.112 mM, 1.12 mM, 2.0 mM, and 6.32 mM into rat vitreous. The toxicity and safety was evaluated with ophthalmoscopy, electroretinography (ERG), and pathology. Vitreous drug levels were determined by HPLC. Results:After intravitreal injection of different concentrations of HDP-P-Ara-C, the rat eyes demonstrated complete clear media without drug precipitates. No clinical toxicity or pathologic abnormality was found. All eyes showed normal ERG at the time of sacrifice (week 2). No HDP-P-Ara-C was detectable at week 2 following intravitreal injection. Conclusion:HDP-P-Ara-C can be synthesized and can be safely administered into vitreous. Failure to form a vitreous drug depot and shorter vitreous duration than HDP-P-GCV may be due to its constituent of cytosine that is water soluble. In contrast, HDP-P-Ara-G with a guanine base may be less water soluble and may provide long intravitreal drug duration as HDP-P-GCV that has guanine component. Such a compound may serve as a long acting antiproliferative agent for vitreoretinal disorders.

Keywords: 390 drug toxicity/drug effects • 514 pharmacology • 524 proliferative vitreoretinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×